Epirubicin and dtic (Edic) for advanced soft-tissue sarcomas

Massimo Lopez, Silvia Carpano, Luigi Di Lauro, Patrizia Vici, Ettore M S Conti

Research output: Contribution to journalArticlepeer-review


Fifty-six patients with measurable advanced soft-tissue sarcomas were treated with epirubicin. 90 mg/m2 intravenously on day I, and DTIC. 250 mg/m2 intravenously on days 1-5, with the entire regimen repeated every 3 weeks. The overall response rate in 52 evaluable patients was 48% with 9 complete remissions. Noncardiac toxicity was limited predominantly to vomiting, alopecia and myelosuppression. Laboratory evidence ofcardiotoxicity [>20% decrease in left-ventricular ejection fraction (LVEF) from the baseline value] was observed in 4 out of 39 patients who had at least two determinations of LVEF, at a median dose of 1.305 mg m2. Two patients had clinical congestive heart failure at cumulative dose of 1.440 and 1.620 mg/m2. These findings suggest that the combination of epirubicin and DTIC is an active regimen in soft-tissue sarcomas, and provide further evidence that epirubicin is a doxorubicin analogue with reduced cardiac toxicity, but preserved efficacy in this disease.

Original languageEnglish
Pages (from-to)230-233
Number of pages4
Issue number3
Publication statusPublished - 1991


  • Chemotherapy
  • Epirubicin
  • Soft-tissue sarcomas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Epirubicin and dtic (Edic) for advanced soft-tissue sarcomas'. Together they form a unique fingerprint.

Cite this